NCCN guidelines for unfavorable inte... - Prostate Cancer N...

Prostate Cancer Network

3,041 members1,736 posts

NCCN guidelines for unfavorable intermediate risk


I thought I did my homework, but now I realize according to the NCCN guidelines, I could've chosen a different path.

I have Gleason 7 (4+3) unfavorable intermediate risk PCa and I chose the HDR Brachytherapy (monotherapy) path.

It looks like EBRT & HDR Brachytherapy is the SOC for unfavorable intermediate risk.


6 Replies

HDR brachy monotherapy has very good results, even in high risk cases, and may have lower risk of side effects:

HDR-BT is quite successful as mono-therapy. Hope your's goes as well as mine did. I'm 6 months out and PSA continues to drop; now at .84 ng/ml. Side effects are minimal.

ocman in reply to CarverD

Thanks, that's great that you're having minimal side effects.

Unfavorable intermediate vs. intermediate can be defined different ways using many different gradings systems. Also some doctors will rule you that way to justify more treatment. I was on the fence as a 50 year old about doing dual treatments and am really glad I chose HDR brachy monotherapy for both its effectiveness and lack of side effects. Per Tall Allen and backed by HDR brachy pioneer Dr Dimanes’ 30+ years of research and treatment, there is plenty of argument for HDR montherapy. This was the doctor that convinced me.

Hi ocman, I had very intense Gleason 4+3, with 9 of 12 biopsy cores cancerous with 5 being 50% or more, and 2 being over 80%. Treated 2 years ago with full course IMRT radiation and 6 months ADT ( Firmagon ) . Still here at 70 and now take Flomax ( tamulosin ) to aid in urination. No regrets at all. All best wishes to you, judg69

ocman in reply to judg69

Thanks brother, best to you too...

You may also like...